Skip to main navigation
How Sol-Gel is Responding to Covid-19
LEARN MORE

Main navigation

  • About
    • Who We Are
    • Management
    • Board of Directors
    • Scientific Advisory Board
  • Pipeline
  • Generics
  • Technology
  • Therapeutic Areas
    • Acne Vulgaris
    • Subtype II Papulopustular Rosacea
    • Palmoplantar Keratoderma
  • Investors
    • Investor Overview
    • Press Releases
    • Events & Presentations
    • Corporate Governance
    • Analyst Coverage
    • Financial Information
    • Stock Information
    • Shareholder Services
  • Contact

Press Releases

Date Title  
Nov 13, 2019
Summary ToggleSol-Gel Technologies Reports Third Quarter 2019 Financial Results and Corporate Update
 
Oct 16, 2019
Summary ToggleSol-Gel to Present on Potential of Sol-Gel Microencapsulation Technology in Rosacea at 39th Annual Fall Clinical Dermatology Conference
 
Aug 13, 2019
Summary ToggleSol-Gel Technologies Reports Second Quarter 2019 Financial Results and Corporate Update
 
Aug 08, 2019
Summary ToggleSol-Gel Announces Pricing of Public Offering of Ordinary Shares
 
Jul 25, 2019
Summary ToggleSol-Gel Technologies Hosting Analyst & Investor Day
 
Jul 08, 2019
Summary ToggleSol-Gel Announces Positive Top-Line Results from Epsolay® Phase 3 Program in Papulopustular Rosacea
 
Jun 17, 2019
Summary ToggleSol-Gel Technologies to Host Analyst & Investor Day on July 25, 2019
 
May 28, 2019
Summary ToggleSol-Gel Technologies Announces Seventh Agreement for Generic Product Candidates with Perrigo
 
May 23, 2019
Summary ToggleSol-Gel to Present at Upcoming Healthcare Investor Conferences in June
 
May 22, 2019
Summary ToggleSol-Gel Technologies Reports First Quarter 2019 Financial Results and Corporate Update
 

Pagination

  • First page First
  • Previous page Previous
  • …
  • Page 3
  • Current page 4
  • Page 5
  • Page 6
  • …
  • Next page Next
  • Last page Last
Displaying 31 - 40 of 65 results

Investor Relations

  • Investor Overview
  • Press Releases
  • Events & Presentations
    • Events
  • Corporate Governance
    • Documents and Charters
    • Committee Composition
  • Analyst Coverage
  • Financial Information
    • SEC Filings
    • Proxy Statement
  • Stock Information
    • Stock Quote & Chart
  • Shareholder Services
    • FAQs
    • Contact
    • Email Alerts

Shareholder Tools

Print
Print
Email Alerts
Email Alerts
RSS Feeds
RSS Feeds

Who We Are

We are a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases.

What We Do

Footer What We Do

  • About
  • Technology
  • Pipeline

Get In Touch

Footer Get In Touch

  • Contact Us
  • Partnering

Subscribe!

Subscribe to receive updates
Sign-up

© 2021 Sol-Gel Technologies Ltd. All Rights Reserved